XML 35 R77.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | $ 121,653 | $ 162,197 | $ 152,933
General & administrative |  |  |  |  |  |  |  |  |  | 65,147 | 53,391 | 64,481
Research and development |  |  |  |  |  |  |  |  |  | 26,768 | 28,577 | 22,861
Amortization of intangible assets |  |  |  |  |  |  |  |  |  | 2,687 | 2,298 | 2,550
Costs related to the accounting review and restatement |  |  |  |  |  |  |  |  |  | 12,945 |  |
Impairment of goodwill |  |  |  |  |  |  |  |  | 19,193 | 19,193 |  |
Charges related to U.S. Government resolutions |  |  |  |  |  |  |  |  |  |  | 1,295 | 57,141
Operating (loss) income | 6,378 | (15,600) | 8,804 | 8,087 | 25,613 | 18,805 | 14,298 | 17,920 |  | (5,087) | 76,636 | 5,900
BioStim [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 64,930 | 86,654 | 93,056
Impairment of goodwill |  |  |  |  |  |  |  |  |  |  |  |
Biologics [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 24,532 | 23,559 | 18,979
Impairment of goodwill |  |  |  |  |  |  |  |  |  |  |  |
Extremity Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 26,389 | 34,337 | 29,530
Impairment of goodwill |  |  |  |  |  |  |  |  | 9,825 |  |  |
Spine Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 7,245 | 19,142 | 13,068
Impairment of goodwill |  |  |  |  |  |  |  |  | 9,368 |  |  |
Corporate [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | $ (1,443) | $ (1,495) | $ (1,700)

X
- Definition Accounting review and restatement costs. + References No definition available. + Details
Name: | ofix_AccountingReviewAndRestatementCosts
Namespace Prefix: | ofix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ofix_SalesInformationLineItems
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Segment Reporting Information Contribution Margin + References No definition available. + Details
Name: | ofix_SegmentReportingInformationContributionMargin
Namespace Prefix: | ofix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration